See more : Vibe Growth Corporation (VIBEF) Income Statement Analysis – Financial Results
Complete financial analysis of Boiron SA (BOIRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Boiron SA, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PT Sidomulyo Selaras Tbk (SDMU.JK) Income Statement Analysis – Financial Results
- New Age Metals Inc. (NAM.V) Income Statement Analysis – Financial Results
- Verra Mobility Corporation (VRRMW) Income Statement Analysis – Financial Results
- Bounce Mobile Systems, Inc. (BNCM) Income Statement Analysis – Financial Results
- M. Dias Branco S.A. Indústria e Comércio de Alimentos (MDIA3.SA) Income Statement Analysis – Financial Results
Boiron SA (BOIRF)
About Boiron SA
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 493.25M | 534.24M | 455.20M | 513.58M | 557.12M | 604.21M | 617.54M | 614.49M | 607.80M | 609.75M | 617.73M | 566.29M | 523.45M | 520.60M | 526.28M | 466.89M | 434.47M | 398.67M | 361.65M | 290.63M | 305.34M | 287.05M | 266.39M |
| Cost of Revenue | 135.17M | 154.51M | 127.58M | 118.84M | 127.22M | 134.65M | 128.15M | 125.15M | 118.98M | 117.56M | 129.40M | 126.87M | 118.60M | 111.28M | 114.07M | 99.61M | 90.34M | 88.42M | 81.04M | 60.57M | 30.79M | 27.43M | 27.13M |
| Gross Profit | 358.08M | 379.73M | 327.62M | 394.74M | 429.90M | 469.57M | 489.39M | 489.34M | 488.82M | 492.19M | 488.33M | 439.43M | 404.86M | 409.32M | 412.21M | 367.29M | 344.13M | 310.25M | 280.60M | 230.07M | 274.55M | 259.62M | 239.26M |
| Gross Profit Ratio | 72.60% | 71.08% | 71.97% | 76.86% | 77.16% | 77.72% | 79.25% | 79.63% | 80.42% | 80.72% | 79.05% | 77.60% | 77.34% | 78.63% | 78.33% | 78.67% | 79.21% | 77.82% | 77.59% | 79.16% | 89.92% | 90.44% | 89.82% |
| Research & Development | 5.77M | 6.09M | 2.99M | 3.52M | 3.13M | 3.83M | 3.59M | 3.95M | 4.21M | 5.40M | 6.28M | 6.64M | 4.56M | 6.34M | 4.28M | 6.57M | 5.71M | 6.07M | 4.97M | 3.43M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 72.81M | 63.74M | 67.43M | 69.43M | 88.01M | 87.82M | 86.13M | 82.92M | 81.44M | 79.85M | 78.42M | 79.39M | 72.30M | 64.81M | 59.78M | 56.97M | 0.00 | 0.00 | -130.91M | 106.01M | 98.69M | 91.87M |
| Selling & Marketing | 232.83M | 236.90M | 212.80M | 244.30M | 273.26M | 284.11M | 280.41M | 274.89M | 276.06M | 268.05M | 271.46M | 275.82M | 266.14M | 268.18M | 251.41M | 243.54M | 238.19M | 90.65M | 78.77M | 163.17M | 0.00 | 0.00 | 0.00 |
| SG&A | 232.83M | 236.90M | 212.80M | 244.30M | 273.26M | 284.11M | 280.41M | 274.89M | 276.06M | 268.05M | 271.46M | 275.82M | 345.53M | 340.48M | 316.22M | 303.32M | 295.16M | 90.65M | 78.77M | 32.26M | 106.01M | 98.69M | 91.87M |
| Other Expenses | 77.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.97M | 0.00 | 0.00 | 2.85M | 0.00 | -613.00K | 1.43M | 0.00 | -790.00K | -1.64M | -578.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 315.79M | 324.21M | 288.08M | 325.01M | 356.36M | 370.44M | 367.21M | 359.85M | 358.64M | 349.13M | 352.90M | 357.11M | 341.16M | 342.67M | 320.44M | 310.10M | 299.45M | 291.28M | 257.14M | 196.38M | 235.03M | 222.78M | 207.90M |
| Cost & Expenses | 450.96M | 478.72M | 415.66M | 443.85M | 483.58M | 505.08M | 495.37M | 484.99M | 477.62M | 466.70M | 482.30M | 483.97M | 459.76M | 453.95M | 434.51M | 409.71M | 389.78M | 379.70M | 338.18M | 256.95M | 265.82M | 250.21M | 235.02M |
| Interest Income | 3.39M | 1.82M | 590.00K | 459.00K | 793.00K | 592.00K | 690.00K | 942.00K | 1.40M | 1.43M | 896.00K | 1.31M | 1.15M | 605.00K | 749.00K | 0.00 | 878.00K | 395.00K | 286.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.19M | 607.00K | 359.00K | 348.00K | 420.00K | 207.00K | 724.00K | 1.13M | 1.20M | 1.22M | 634.00K | 669.00K | 229.00K | 0.00 | -24.00K | 367.00K | 693.00K | 995.00K | 927.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.63M | 17.21M | 18.12M | 69.26M | 32.95M | 31.52M | 29.37M | 28.20M | 29.43M | 18.37M | 33.00M | 34.16M | 18.89M | 35.47M | 19.11M | 24.53M | 17.64M | 18.39M | 23.70M | 14.56M | 17.17M | 14.64M | 10.48M |
| EBITDA | 73.67M | 77.02M | 64.60M | 106.82M | 116.74M | 139.92M | 159.38M | 162.12M | 154.08M | 160.92M | 164.87M | 117.17M | 86.57M | 102.12M | 110.88M | 81.51M | 63.04M | 37.61M | 49.01M | 48.46M | 56.69M | 51.48M | 42.94M |
| EBITDA Ratio | 14.94% | 12.89% | 13.07% | 26.47% | 19.82% | 21.88% | 24.15% | 25.58% | 25.88% | 25.90% | 26.76% | 20.54% | 16.54% | 19.62% | 21.07% | 18.29% | 14.46% | 9.43% | 13.59% | 16.74% | 18.57% | 17.93% | 16.12% |
| Operating Income | 42.29M | 63.45M | 46.84M | 38.19M | 66.92M | 106.02M | 124.98M | 129.66M | 126.55M | 144.18M | 134.31M | 81.11M | 63.70M | 66.65M | 91.77M | 57.19M | 44.69M | 19.28M | 24.65M | 33.22M | 39.52M | 36.84M | 31.36M |
| Operating Income Ratio | 8.57% | 11.88% | 10.29% | 7.44% | 12.01% | 17.55% | 20.24% | 21.10% | 20.82% | 23.65% | 21.74% | 14.32% | 12.17% | 12.80% | 17.44% | 12.25% | 10.29% | 4.84% | 6.82% | 11.43% | 12.94% | 12.83% | 11.77% |
| Total Other Income/Expenses | 4.56M | -4.25M | -729.00K | -968.00K | -2.53M | -2.03M | -1.85M | -2.76M | -3.10M | -2.85M | -3.07M | -2.22M | 3.76M | 258.00K | 773.00K | 3.30M | -196.00K | -657.00K | -268.00K | 675.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 46.85M | 59.20M | 46.11M | 37.22M | 64.39M | 103.99M | 123.13M | 126.90M | 123.45M | 141.32M | 131.24M | 82.34M | 67.46M | 66.91M | 91.15M | 60.48M | 44.49M | 18.62M | 24.38M | 33.90M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 9.50% | 11.08% | 10.13% | 7.25% | 11.56% | 17.21% | 19.94% | 20.65% | 20.31% | 23.18% | 21.25% | 14.54% | 12.89% | 12.85% | 17.32% | 12.95% | 10.24% | 4.67% | 6.74% | 11.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.91M | 14.92M | 17.55M | 11.01M | 23.80M | 46.54M | 44.93M | 49.19M | 49.54M | 52.27M | 48.87M | 32.73M | 25.19M | 23.63M | 31.27M | 21.30M | 17.33M | 8.36M | 7.96M | 13.28M | 13.89M | 13.82M | 12.76M |
| Net Income | 35.83M | 44.67M | 28.56M | 26.21M | 40.63M | 57.46M | 78.24M | 77.73M | 73.93M | 89.05M | 82.40M | 49.63M | 42.26M | 43.28M | 59.89M | 39.18M | 27.16M | 10.25M | 16.42M | 20.59M | 25.63M | 23.02M | 19.70M |
| Net Income Ratio | 7.26% | 8.36% | 6.27% | 5.10% | 7.29% | 9.51% | 12.67% | 12.65% | 12.16% | 14.60% | 13.34% | 8.76% | 8.07% | 8.31% | 11.38% | 8.39% | 6.25% | 2.57% | 4.54% | 7.09% | 8.39% | 8.02% | 7.39% |
| EPS | 2.06 | 2.57 | 1.63 | 1.50 | 2.32 | 3.23 | 4.25 | 4.22 | 4.01 | 4.62 | 4.24 | 2.33 | 1.97 | 2.02 | 2.78 | 1.80 | 1.25 | 0.47 | 0.81 | 1.11 | 1.38 | 1.24 | 1.06 |
| EPS Diluted | 2.06 | 2.57 | 1.63 | 1.50 | 2.32 | 3.23 | 4.25 | 4.22 | 4.01 | 4.62 | 4.24 | 2.33 | 1.97 | 2.02 | 2.78 | 1.80 | 1.25 | 0.47 | 0.81 | 1.11 | 1.38 | 1.24 | 1.06 |
| Weighted Avg Shares Out | 17.36M | 17.39M | 17.52M | 17.51M | 17.51M | 17.79M | 18.43M | 18.43M | 18.45M | 19.27M | 19.42M | 21.28M | 21.46M | 21.46M | 21.55M | 21.76M | 21.75M | 21.89M | 20.29M | 18.60M | 18.58M | 18.57M | 18.60M |
| Weighted Avg Shares Out (Dil) | 17.36M | 17.39M | 17.52M | 17.51M | 17.51M | 17.79M | 18.43M | 18.43M | 18.45M | 19.27M | 19.42M | 21.28M | 21.46M | 21.46M | 21.55M | 21.76M | 21.75M | 21.89M | 20.29M | 18.60M | 18.58M | 18.57M | 18.60M |
Source: https://incomestatements.info
Category: Stock Reports